Abstract
The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 178-183 |
| Number of pages | 6 |
| Journal | Canadian Journal of Veterinary Research |
| Volume | 82 |
| Issue number | 3 |
| State | Published - Jul 1 2018 |
Fingerprint
ASJC Scopus subject areas
- veterinary(all)
Cite this
Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. / Bartner, Lisa R.; McGrath, Stephanie; Rao, Sangeeta; Hyatt, Linda K.; Wittenburg, Luke Anthony.
In: Canadian Journal of Veterinary Research, Vol. 82, No. 3, 01.07.2018, p. 178-183.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs
AU - Bartner, Lisa R.
AU - McGrath, Stephanie
AU - Rao, Sangeeta
AU - Hyatt, Linda K.
AU - Wittenburg, Luke Anthony
PY - 2018/7/1
Y1 - 2018/7/1
N2 - The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.
AB - The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.
UR - http://www.scopus.com/inward/record.url?scp=85050011153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050011153&partnerID=8YFLogxK
M3 - Article
VL - 82
SP - 178
EP - 183
JO - Canadian Journal of Veterinary Research
JF - Canadian Journal of Veterinary Research
SN - 0830-9000
IS - 3
ER -